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Uveal melanoma is the most common intraocular malignancy in adults. The lack of an effective 
treatment results in a median survival time less than one year for patients with metastatic disease. 
Recently, our lab identified the melanoma-specific long non-coding RNA (lncRNA) SAMMSON as a 
novel therapeutic target in skin melanoma. 
Analysis of a PAN cancer RNA-sequencing dataset revealed consistent expression of SAMMSON in 
uveal melanoma tumors. Although SAMMSON expression was lower in uveal compared to skin 
melanoma, over 90% of uveal melanoma tumors showed detectable SAMMSON expression. Further 
analysis also revealed SAMMSON expression in conjunctival melanoma, another form of ocular 
melanoma. To evaluate the therapeutic potential of SAMMSON inhibition in uveal and conjunctival 
melanoma, we treated a panel of representative cell lines with SAMMSON-specific antisense 
oligonucleotides (ASOs) and observed a strong reduction in cell viability, accompanied by induction 
of apoptosis. These effects were dependent on ASO dosing and were validated using 8 independent 
SAMMSON-targeting ASOs and various ASO chemistries. ASO-treatment of a uveal melanoma PDX 
model further confirmed the observed phenotype. In line with the function of SAMMSON in 
modulating mitochondrial metabolism, SAMMSON knock down resulted in a decreased 
mitochondrial oxidative phosphorylation. Together, our results demonstrate the efficacy of 
SAMMSON inhibition as a novel treatment option for uveal melanoma patients. 
 
 
 
 
